Formycon AG Logo

Formycon AG

FYB | F

Overview

Corporate Details

ISIN(s):
DE000A1EWVY8
LEI:
39120005TZ76GQOY8Z19
Country:
Germany
Address:
Fraunhoferstraße 15, 82152 Planegg
Sector:
Health Care
Industry:
Biotechnology

Description

Formycon is a world-leading, independent developer of high-quality biosimilars, meaning follow-on products to biopharmaceutical medicines already on the market. Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company’s activities span the entire range from technical- pharmaceutical development to clinical trials all the way through to preparation and submission of dossiers for regulatory approval. We develop biosimilar medicines to meet the high standards of the world’s most stringently regulated markets: the European Union, the United States, Canada, Japan and Australia. We will continue to expand our position as a globally operating company in the growth market of biosimilars in line with our growth strategy.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 15:51
Capital/Financing Update
Formycon increases bond volume following oversubscription Bond 2025/2029 with …
English 14.9 KB
2025-06-26 06:30
Regulatory News Service
Teva becomes secondary commercialization partner for Formycon's Stelara biosimi…
English 15.6 KB
2025-06-25 06:30
Regulatory News Service
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization part…
English 17.0 KB
2025-06-24 19:50
Capital/Financing Update
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscriptio…
English 19.6 KB
2025-06-20 09:00
Capital/Financing Update
Formycon bond 2025/2029: Public subscription now also possible via Deutsche Bor…
English 19.8 KB
2025-06-18 16:43
Declaration of Voting Results & Voting Rights Announcements
Ordinary Annual General Meeting of Formycon AG approves all proposed resolution…
English 12.9 KB
2025-06-18 06:25
Capital/Financing Update
Formycon AG: Subscription period for 2025/2029 corporate bond has started
English 20.5 KB
2025-06-17 08:01
Capital/Financing Update
Formycon plans public corporate bond issuance to support next growth phase with…
English 21.3 KB
2025-06-05 06:30
Regulatory News Service
Lucentis biosimilar FYB201/Ranivisio (ranibizumab) approved in Brazil
English 14.5 KB
2025-05-27 14:30
Regulatory News Service
Formycon and Fresenius Kabi announce the commercial launch of FYB202/OtulfiTM, …
English 15.2 KB
2025-05-19 15:00
Regulatory News Service
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB…
English 14.2 KB
2025-05-15 00:00
Regulatory News Service
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 5.8 MB
2025-05-14 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 23.0 MB
2025-05-12 06:30
Earnings Release
Formycon reports strong operational performance and financial results for first…
English 25.8 KB
2025-05-12 00:00
Earnings Release
Q1 statement / Q1 financial report 2025
English 208.3 KB

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-21 Seidl, Dr. Andreas Board Buy None 4,800.00 EUR
2024-04-29 Mikulcik, Dr. Marc Close relation Buy None 48,000.00 EUR
2024-04-24 Glombitza, Dr. Stefan Board Buy None 97,444.00 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo 1NKEMIA Spain IKM
2cureX AB Logo 2cureX AB Sweden 2CUREX
4SC AG Logo 4SC AG Germany VSC
Abera Bioscience AB Logo Abera Bioscience AB Sweden ABERA
ABIONYX Pharma Logo ABIONYX Pharma France ABNX
Abliva Logo Abliva Sweden ABLI
AB Science Logo AB Science France AB
Acticor Biotech Logo Acticor Biotech France ALACT
Active Biotech Logo Active Biotech Sweden ACTI
AcuCort AB Logo AcuCort AB Sweden ACUC